RIGL Q1 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+80.6% YoY

Gross Profit

$49M91.7% margin

Operating Income

$13M23.9% margin

Net Income

$11M21.5% margin

EPS (Diluted)

$0.63

QoQ Revenue Growth

-7.4%

Cash Flow

Operating Cash Flow

-$893,000

Free Cash Flow

-$893,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$176M

Total Liabilities

$157M

Stockholders' Equity

$19M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$30M	+80.6%
Gross Profit	$49M	$28M	+77.8%
Operating Income	$13M	-$7M	+283.4%
Net Income	$11M	-$8M	+238.8%

Revenue Segments

Gross product sales

$60M60%

Product sales, net

$44M44%

Contract revenues from collaborations

$10M10%

Milestone

$3M3%

Discounts and allowances

-$17M-17%